Pharmather seeks to commercialize generic semaglutide

Executive Summary

• Pharmather Holdings Ltd. has launched a strategic initiative to pursue Health Canada approval for generic semaglutide (the active ingredient in Ozempic and Wegovy) for commercialization in Canada.
• The initiative leverages the company's previous success with FDA-approved ketamine, which was monetized with potential proceeds exceeding $25 million (U.S.).
• The move targets an early major market opportunity following the expiration of regulatory exclusivity for semaglutide in Canada in January 2026.

Key Details

• Target Product: Generic semaglutide (sterile injectable), covering doses from 0.25 mg to 2.4 mg.
• Regulatory Timeline: The company aims to pursue Health Canada approval in 2026.
• Market Context:
  • Regulatory exclusivity for semaglutide in Canada expired in January 2026.
  • Ozempic generated approximately $2.9 billion (Canadian) in Canadian sales in 2025.
  • The broader GLP-1 receptor agonist opportunity in Canada is estimated to grow to approximately $6.5 billion (U.S.) by 2033.
• Manufacturing Strategy: Utilizing a cost-effective, high-quality commercial sterile injectable manufacturer with facilities audited by regulatory health authorities to ensure supply reliability.
• Strategic Goal: To position Pharmather among early suppliers of generic semaglutide in Canada and build a scalable sterile injectable platform for future global partnering opportunities in the obesity and diabetes markets.
• Past Precedent: The initiative builds on Pharmather's execution regarding FDA approval of ketamine and the monetization of U.S. rights with potential proceeds exceeding $25 million (U.S.).

Notable Quotes

• "Canada's semaglutide market is entering a pivotal transition: Demand is growing, and affordable access and reliable supply will matter," said Fabio Chianelli, founder, chairman and chief executive officer of Pharmather. "We've already proven we can execute on FDA approval of injectable drugs and structure a meaningful pharma partnership in ketamine. We are now applying that same execution playbook to pursue Health Canada approval for generic semaglutide and build a scalable sterile injectable platform for the obesity and diabetes market."